Actinium Competitors
| ATNM Stock | USD 1.16 0.07 5.69% |
Actinium Pharmaceuticals vs Annovis Bio Correlation
Modest diversification
The correlation between Actinium Pharmaceuticals and ANVS is 0.27 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Actinium Pharmaceuticals and ANVS in the same portfolio, assuming nothing else is changed.
Moving against Actinium Stock
As of the 31st of January 2026, Return On Tangible Assets is likely to grow to -0.43. In addition to that, Return On Capital Employed is likely to grow to -0.67. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 31st of January 2026, Total Current Assets is likely to grow to about 90 M, while Other Assets are likely to drop 1.09.Actinium Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Actinium Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Actinium and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Actinium Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Actinium Stock performing well and Actinium Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Actinium Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PDSB | 4.02 | (0.06) | 0.00 | 0.02 | 4.67 | 8.60 | 27.78 | |||
| LVTX | 1.33 | 0.22 | 0.08 | (0.35) | 1.19 | 4.70 | 14.75 | |||
| XLO | 2.15 | (0.39) | 0.00 | (0.51) | 0.00 | 4.69 | 15.41 | |||
| TPST | 4.69 | (1.55) | 0.00 | (2.09) | 0.00 | 7.92 | 57.69 | |||
| OKUR | 4.09 | 0.02 | 0.00 | 0.13 | 4.36 | 9.79 | 23.27 | |||
| RVPH | 5.91 | (0.64) | 0.00 | (0.55) | 0.00 | 10.71 | 65.06 | |||
| FGEN | 2.66 | (0.23) | 0.00 | (0.44) | 0.00 | 4.33 | 28.75 | |||
| KZR | 0.72 | (0.01) | (0.05) | (0.01) | 1.04 | 1.46 | 7.79 | |||
| TVRD | 2.68 | (0.37) | 0.00 | (0.31) | 0.00 | 5.59 | 17.33 | |||
| ANVS | 5.17 | 0.85 | 0.14 | 72.97 | 5.23 | 14.79 | 41.06 |
Cross Equities Net Income Analysis
Compare Actinium Pharmaceuticals and related stocks such as PDS Biotechnology Corp, LAVA Therapeutics, and Xilio Development Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.9 M) | (12.2 M) | (28.1 M) | (38.8 M) | (50.9 M) | (40.9 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (42.9 M) | (37.6 M) | (33.8 M) | (35.5 M) |
| XLO | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (55.2 M) | (74.3 M) | (87.3 M) | (76.4 M) | (58.2 M) | (52.4 M) | (55 M) |
| TPST | (2.7 M) | (2.7 M) | (13.5 M) | (29 M) | (49.5 M) | (73.2 M) | (82.3 M) | (84.6 M) | (27.2 M) | (44.6 M) | (19.1 M) | (28.3 M) | (35.7 M) | (29.5 M) | (41.8 M) | (37.7 M) | (39.5 M) |
| OKUR | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (39.8 M) | (29.5 M) | (35.3 M) | (52.7 M) | (47.4 M) | (49.8 M) |
| RVPH | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (846.8 K) | (3.8 M) | (8.5 M) | (24.3 M) | (39.3 M) | (29.9 M) | (26.9 M) | (25.6 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (54.6 M) | (65.3 M) | (101.9 M) | (83.7 M) | (75.4 M) | (71.6 M) |
| TVRD | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | (88.4 M) | (85.5 M) | (118.5 M) | (70.9 M) | (63.8 M) | (67 M) |
| ANVS | (369.6 K) | (4.7 M) | (8.3 M) | (682.3 K) | (682.3 K) | (682.3 K) | (682.3 K) | (682.3 K) | (713.9 K) | (991 K) | (5.5 M) | (14.5 M) | (25.1 M) | (56.2 M) | (24.6 M) | (22.1 M) | (21 M) |
Actinium Pharmaceuticals and related stocks such as PDS Biotechnology Corp, LAVA Therapeutics, and Xilio Development Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Actinium Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Actinium Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Actinium Pharmaceuticals Competitive Analysis
The better you understand Actinium Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Actinium Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Actinium Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Actinium Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Actinium Pharmaceuticals Competition
Actinium Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Actinium Pharmaceuticals in relation to its competition. Actinium Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Actinium Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Actinium Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Actinium Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Actinium Pharmaceuticals position
In addition to having Actinium Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run USD Crypto Fund Thematic Idea Now
USD Crypto Fund
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Actinium Pharmaceuticals Correlation with its peers. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Actinium diversify its offerings? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Actinium Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.11) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Actinium Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Actinium's accounting equity. The concept of intrinsic value—what Actinium Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Actinium Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Actinium Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actinium Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Actinium Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.